Literature DB >> 9636833

Survival of patients with visceral metastatic melanoma from an occult primary lesion: a retrospective matched cohort study.

G Vijuk1, A S Coates.   

Abstract

BACKGROUND: Malignant melanoma presents as metastatic disease without an apparent primary in about 4% of cases. These are referred to as occult primary melanoma (OPM). It is not known whether these represent de novo malignant transformation in non-cutaneous sites or the disappearance of an unrecognised primary, perhaps on an immunological basis. We hypothesised that OPM might have a superior prognosis compared to patients with similar disease extent from a known primary lesion (KPM). PATIENTS AND METHODS: We performed a retrospective cohort survival study of 146 patients with OPM and visceral metastases treated at the Sydney Melanoma Unit between 1983 and 1996. A control group of patients with KPM was matched for age, sex and site of visceral metastases. Survival was measured from the date of diagnosis of visceral metastases.
RESULTS: Patients with OPM had a median survival of 233 days, significantly longer than the 176 days for those with KPM (P = 0.024; logrank test). Multivariate analysis allowing for simultaneous or prior involvement of lymph nodes, subcutaneous tissues or bone, and site of visceral involvement showed a significantly superior survival for OPM (hazard ratio (HR): 0.72; 95% confidence interval (CI): 0.55-0.93). A small part of the effect was explained by treatment, but models allowing for this still showed a significantly longer survival.
CONCLUSIONS: Survival was longer in OPM patients. This may reflect an intrinsically superior host-tumour interaction.

Entities:  

Mesh:

Year:  1998        PMID: 9636833     DOI: 10.1023/a:1008201931959

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  17 in total

1.  Surgical resection of malignant melanoma metastatic to the pancreas: case series and review of literature.

Authors:  Jatinder Goyal; Evan J Lipson; Neda Rezaee; Barish H Edil; Rich Schulick; Christopher L Wolfgang; Ralph H Hruban; Emmanuel S Antonarakis
Journal:  J Gastrointest Cancer       Date:  2012-09

Review 2.  Genetic factors in metastatic progression of cutaneous melanoma: the future role of circulating melanoma cells in prognosis and management.

Authors:  A Ireland; M Millward; R Pearce; M Lee; M Ziman
Journal:  Clin Exp Metastasis       Date:  2011-02-11       Impact factor: 5.150

3.  Melanoma with unknown primary: report and analysis of 24 patients.

Authors:  Rita Clerico; Ugo Bottoni; Giovanni Paolino; Marina Ambrifi; Paola Corsetti; Valeria Devirgiliis; Stefano Calvieri
Journal:  Med Oncol       Date:  2012-03-30       Impact factor: 3.064

4.  Improved survival for stage IV melanoma from an unknown primary site.

Authors:  Chris C Lee; Mark B Faries; Leslie A Wanek; Donald L Morton
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

5.  Solitary dermal melanoma: beginning or end of the metastatic process?

Authors:  Chris C Lee; Mark B Faries; Xing Ye; Donald L Morton
Journal:  Ann Surg Oncol       Date:  2009-01-06       Impact factor: 5.344

6.  Stage IV melanoma of unknown primary: A population-based study in the United States from 1973 to 2014.

Authors:  Jeffrey F Scott; Ruzica Z Conic; Cheryl L Thompson; Meg R Gerstenblith; Jeremy S Bordeaux
Journal:  J Am Acad Dermatol       Date:  2018-03-23       Impact factor: 11.527

7.  Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis.

Authors:  Deborah Kuk; Alexander N Shoushtari; Christopher A Barker; Katherine S Panageas; Rodrigo R Munhoz; Parisa Momtaz; Charlotte E Ariyan; Mary Sue Brady; Daniel G Coit; Kita Bogatch; Margaret K Callahan; Jedd D Wolchok; Richard D Carvajal; Michael A Postow
Journal:  Oncologist       Date:  2016-06-10

8.  Metastatic malignant melanoma of the inguinal lymph node with unknown primary lesion.

Authors:  Sherif Ali Eltawansy; Ryane Panasiti; Samaa Hasanien; Dennis Lourdusamy; David Sharon
Journal:  Case Rep Med       Date:  2015-02-01

9.  Results of systemic treatment of cutaneous melanoma in inoperable stage III and IV.

Authors:  Bożena Cybulska-Stopa; Marta Skoczek; Marek Ziobro; Tomasz Switaj; Sławomir Falkowski; Tadeusz Morysiński; Marcin Hetnał; Ida Cedrych; Piotr Rutkowski
Journal:  Contemp Oncol (Pozn)       Date:  2013-01-04

10.  Diagnostic accuracy of fine needle biopsy for metastatic melanoma and its implications for patient management.

Authors:  Anna Doubrovsky; Richard A Scolyer; Rajmohan Murali; Paul R McKenzie; Geoffrey F Watson; C Soon Lee; Duncan J McLeod; William H McCarthy; Roger F Uren; Jonathan R Stretch; Robyn P Saw; John F Thompson
Journal:  Ann Surg Oncol       Date:  2007-11-08       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.